focus -WSS

focus

author：leisure time 2025-09-30 17:04:25 - browse：46

Empty biotech lab with no people and green benches and cabinets. -- biotech coverage from STAT — Adobe

Demand for new lab space has plummeted by more than half since the end of 2021, and life science vacancy rates are the highest they’ve been in a decade amid the biotech industry’s ongoing downturn, according to a report released Tuesday by Jones Lang LaSalle, a commercial real estate services company

Tenant demand, measured by the total amount of new space that companies are looking to lease, dropped from 25.3 million square feet at the end of 2021 to 10.1 million square feet by the second quarter of this year across eight top life science markets: Boston, the Bay Area, San Diego, Raleigh-Durham, Philadelphia, Seattle, Los Angeles, and the Washington, D.C., area.

The real estate numbers presented in JLL’s annual life sciences report are yet another sign that the biotech industry, which outperformed the broader market for years, is in the midst of a slowdown. Lab space is increasingly going unused amid a supply glut, and more companies are looking to sublease space. Real estate observers say there are some signs these trends could turn around in the next year or two, though that is far from certain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： STAT Readout: Friday, Oct. 20 biotech updates

leisure time

hotspot

WSS

STAT Summit: The economic case for universal basic health care

A disappointing year of Humira biosimilars

STAT Readout: Friday, Oct. 20 biotech updates

Smaller biotechs seek to piggyback on weight loss drug boom

The dental labor crisis is a moment of opportunity

What should King Charles tell the public about his cancer?

Wikipedia

focus

focus

At least 13 dead in Texas as scorching temps continue

Key House Republican on health care plans exit from Congress

Novavax promises a turnaround & Lilly roils the obesity market

Industry veterans launch new biotech VC with $310M

Medicare details structure of new drug price negotiation program

How digital tools helped lower hypertension in marginalized patients

In age of alternative facts, a scholarly course on calling out crap

Senators start work on Medicare physician payment reform

Virginia high school admissions case could be legal follow

BioAge raises $170M for combination therapy with Zepbound

entertainment

PhRMA lawsuit over Medicare drug price negotiation tossed

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Is there really a nursing shortage in the U.S.?

UnitedHealth, Optum discontinue NaviHealth name

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

focus

leisure time

hotspot

hotspot